NOVARTINDPharmaceuticals
Novartis India Ltd — Cash Flow Statement
₹672.25
+0.00%
Novartis India Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 74.57 Cr | 113.40 Cr | 44.49 Cr | 38.17 Cr | — |
| End Cash Position | 52.07 Cr | 44.96 Cr | 19.42 Cr | 158.35 Cr | — |
| Beginning Cash Position | 44.96 Cr | 19.42 Cr | 158.35 Cr | 68.27 Cr | — |
| Changes In Cash | 7.11 Cr | 25.54 Cr | -138.93 Cr | 90.08 Cr | — |
| Financing Cash Flow | -64.15 Cr | -120.99 Cr | -30.48 Cr | -35.63 Cr | — |
| Interest Paid Cff | -0.01 Cr | -0.01 Cr | -0.05 Cr | -0.04 Cr | — |
| Cash Dividends Paid | -61.73 Cr | -117.28 Cr | -24.69 Cr | -24.69 Cr | — |
| Investing Cash Flow | -3.31 Cr | 33.13 Cr | -153.25 Cr | 87.04 Cr | — |
| Interest Received Cfi | 41.27 Cr | 34.69 Cr | 19.98 Cr | 15.54 Cr | — |
| Net Investment Purchase And Sale | -44.90 Cr | -4.83 Cr | -176.86 Cr | 72.00 Cr | — |
| Sale Of Investment | 1.11K Cr | 1.04K Cr | 964.14 Cr | 1.82K Cr | — |
| Purchase Of Investment | -1.15K Cr | -1.04K Cr | -1.14K Cr | -1.75K Cr | — |
| Net PPE Purchase And Sale | 0.32 Cr | 0.00 | 0.07 Cr | -0.50 Cr | — |
| Sale Of PPE | 0.32 Cr | 0.00 | 0.38 Cr | 0.00 | — |
| Operating Cash Flow | 74.57 Cr | 113.40 Cr | 44.80 Cr | 38.67 Cr | — |
| Taxes Refund Paid | -16.29 Cr | 38.27 Cr | 2.34 Cr | -18.59 Cr | — |
| Change In Working Capital | -0.76 Cr | 9.04 Cr | -24.00 Cr | 66.72 Cr | — |
| Change In Other Current Liabilities | -8.98 Cr | -10.06 Cr | 0.59 Cr | -17.45 Cr | — |
| Change In Other Current Assets | 13.41 Cr | 16.97 Cr | 12.01 Cr | 54.62 Cr | — |
| Change In Payable | -9.25 Cr | 2.12 Cr | -10.02 Cr | 14.83 Cr | — |
| Change In Inventory | 3.75 Cr | 9.86 Cr | 2.35 Cr | -9.12 Cr | — |
| Change In Receivables | 1.50 Cr | -5.34 Cr | 9.07 Cr | -4.85 Cr | — |
| Other Non Cash Items | -40.73 Cr | -56.98 Cr | -53.39 Cr | -17.38 Cr | — |
| Stock Based Compensation | 0.33 Cr | 0.25 Cr | 0.38 Cr | 1.85 Cr | — |
| Provisionand Write Offof Assets | 0.01 Cr | 0.31 Cr | 0.62 Cr | 0.55 Cr | — |
| Depreciation And Amortization | 2.19 Cr | 2.61 Cr | 6.06 Cr | 9.65 Cr | — |
| Depreciation | 2.19 Cr | 2.61 Cr | 6.06 Cr | 9.65 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.32 Cr | 0.10 Cr | -0.07 Cr | -0.09 Cr | — |
| Gain Loss On Sale Of PPE | -0.11 Cr | 0.00 | -0.24 Cr | 0.14 Cr | — |
| Net Income From Continuing Operations | 130.42 Cr | 122.84 Cr | 115.38 Cr | -3.82 Cr | — |
| Net Other Investing Changes | — | 3.27 Cr | 3.56 Cr | — | — |
| Purchase Of PPE | — | 0.00 | -0.31 Cr | -0.50 Cr | -0.09 Cr |
| Gain Loss On Investment Securities | — | -3.21 Cr | -2.65 Cr | — | -4.49 Cr |
| Capital Expenditure | — | — | -0.31 Cr | -0.50 Cr | -0.09 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Novartis India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.